Insider · CIK 0001296528

Richard John P

Reports to the SEC for 3 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001296528

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-03-13	GYREGYRE THERAPEUTICS, INC.P Purchase	Director	PPurchase	+2,500 sh	$3.98	+$9,950	3,716
2019-10-11	VXRTVaxart, Inc.P Purchase	Director	PPurchase	+20K sh	$0.38	+$7,680	20,000
2019-06-13	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2019-06-12	VXRTVaxart, Inc. · Stock Option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2019-06-12	VXRTVaxart, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.7K sh	—	—	12,700
2019-05-24	GYREGYRE THERAPEUTICS, INC.P Purchase	Director	PPurchase	+1,000 sh	$8.03	+$8,030	1,216
2018-06-13	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2018-02-20	GYREGYRE THERAPEUTICS, INC. · Redeemable Convertible NoteJ Other	Director	JOther	—	—	—	—
2017-12-20	GYREGYRE THERAPEUTICS, INC. · Redeemable Convertible NoteJ Other	Director	JOther	—	—	—	—
2017-07-13	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2017-05-18	VXRTVaxart, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	$0.49	+$9,800	105,000
2016-06-09	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2016-05-12	VXRTVaxart, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	$1.50	+$30K	20,000
2015-10-22	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+8,250 sh	—	—	8,250
2015-10-22	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+6,750 sh	—	—	6,750
2015-10-22	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+6,750 sh	—	—	6,750
2015-08-14	GYREGYRE THERAPEUTICS, INC. · Redeemable Convertible NoteA Award	Director	AAward	—	—	—	—
2015-08-11	VXRTVaxart, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2015-05-12	VXRTVaxart, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2014-12-11	GYREGYRE THERAPEUTICS, INC.A Award	Director	AAward	+10K sh	—	—	15,333
2014-01-08	GYREGYRE THERAPEUTICS, INC. · Common Stock, $0.001 par value per shareA Award	Director	AAward	+10K sh	—	—	10,000
2014-01-08	GYREGYRE THERAPEUTICS, INC. · Common Stock, $0.001 par value per shareA Award	Director	AAward	−10K sh	—	—	10,000
2013-08-13	VXRTVaxart, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2013-06-07	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2012-06-08	GYREGYRE THERAPEUTICS, INC.P Purchase	Director	PPurchase	+7,500 sh	$4.16	+$31.2K	7,500
2012-06-07	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2011-07-01	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$9.27	+$23.2K	7,833
2011-07-01	GYREGYRE THERAPEUTICS, INC.S Sale	Director	SSale	−2,500 sh	$21.02	−$52.6K	5,333
2011-07-01	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	2,500
2011-06-15	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2011-04-01	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$9.27	+$23.2K	7,833
2011-04-01	GYREGYRE THERAPEUTICS, INC.S Sale	Director	SSale	−2,500 sh	$26.60	−$66.5K	5,333
2011-04-01	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	5,000
2011-01-19	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$2.71	+$13.6K	10,333
2011-01-19	GYREGYRE THERAPEUTICS, INC.S Sale	Director	SSale	−5,000 sh	$27.11	−$136K	5,333
2011-01-19	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	0
2011-01-18	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,500 sh	$2.71	+$6,775	7,833
2011-01-18	GYREGYRE THERAPEUTICS, INC.S Sale	Director	SSale	−2,500 sh	$27.38	−$68.4K	5,333
2011-01-18	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,500 sh	—	—	5,000
2010-06-17	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2010-05-14	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+1,000 sh	$0.07	+$75	6,333
2010-05-14	GYREGYRE THERAPEUTICS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$7.10	+$53.3K	13,833
2010-05-14	GYREGYRE THERAPEUTICS, INC.S Sale	Director	SSale	−8,500 sh	$24.22	−$206K	5,333
2010-05-14	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,000 sh	—	—	0
2010-05-14	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	0
2009-07-01	Altus Pharmaceuticals Inc.Common Stock Option (right to buy)A Award	Director	AAward	+9,812 sh	—	—	9,812
2009-06-17	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2008-07-02	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2007-06-27	Altus Pharmaceuticals Inc.Common Stock Option (right to buy)A Award	Director	AAward	+13.1K sh	—	—	13,083
2007-06-20	GYREGYRE THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+7,500 sh	—	—	7,500

Recent filings

Accepted (ET)
Mar 134
Richard John P0001209191-20-019038
SEC(opens sec.gov)
Oct 154
Richard John P0001437749-19-020035
SEC(opens sec.gov)
Jun 174
Richard John P0001209191-19-037569
SEC(opens sec.gov)
Jun 144
Richard John P0001437749-19-012099
SEC(opens sec.gov)
May 284
Richard John P0001209191-19-032871
SEC(opens sec.gov)
Jun 154
Richard John P0001209191-18-038138
SEC(opens sec.gov)
Feb 224
Richard John P0001209191-18-012450
SEC(opens sec.gov)
Dec 224
Richard John P0001209191-17-067088
SEC(opens sec.gov)
Jul 174
Richard John P0001209191-17-045311
SEC(opens sec.gov)
May 224
Aviragen Therapeutics, Inc.0001437749-17-009783
SEC(opens sec.gov)
Jun 134
CATALYST BIOSCIENCES, INC.0001209191-16-127369
SEC(opens sec.gov)
May 134
Aviragen Therapeutics, Inc.0001437749-16-031865
SEC(opens sec.gov)
Dec 154/A
CATALYST BIOSCIENCES, INC.0001209191-15-085394
SEC(opens sec.gov)
Oct 264
CATALYST BIOSCIENCES, INC.0001209191-15-076823
SEC(opens sec.gov)
Aug 184
TARGACEPT INC0000899243-15-003387
SEC(opens sec.gov)
Aug 134
Biota Pharmaceuticals, Inc.0001437749-15-015757
SEC(opens sec.gov)
May 144
Biota Pharmaceuticals, Inc.0001437749-15-010165
SEC(opens sec.gov)
Dec 124
TARGACEPT INC0001181431-14-038783
SEC(opens sec.gov)

Companies

Address

C/O ALTUS PHARMACEUTICALS INC. 610 LINCOLN STREET

WALTHAM, MA, 02451